<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258336</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000449719</org_study_id>
    <secondary_id>FAV-ID-70</secondary_id>
    <secondary_id>FAV-ID-LYM-31</secondary_id>
    <nct_id>NCT00258336</nct_id>
  </id_info>
  <brief_title>Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Trial of Maintenance Rituximab Plus FavId® and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Favrille</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others&#xD;
      interfere with the ability of cancer cells to grow and spread. Vaccines made from a person's&#xD;
      cancer cells may help the body build an effective immune response to kill cancer cells.&#xD;
      Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in&#xD;
      bone marrow or peripheral blood. Giving rituximab together with vaccine therapy and GM-CSF&#xD;
      may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving rituximab together with vaccine&#xD;
      therapy and GM-CSF works in treating patients with indolent B-cell non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of immunotherapy comprising rituximab, autologous immunoglobulin&#xD;
           idiotype-KLH conjugate vaccine (FavId™), and sargramostim (GM-CSF), in terms of response&#xD;
           rate (partial and complete) and event-free survival, in patients with indolent B-cell&#xD;
           non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Evaluate development of an immune response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
        -  Induction therapy: Patients receive rituximab IV over 2-4 hours once weekly for 4 weeks.&#xD;
           Patients are evaluated for response at month 3. Patients with responding or stable&#xD;
           disease proceed to maintenance therapy. Patients with progressive disease are removed&#xD;
           from study.&#xD;
&#xD;
        -  Maintenance therapy: Patients receive rituximab as in induction therapy in months 7, 13,&#xD;
           and 19. Patients also receive autologous immunoglobulin idiotype-KLH conjugate vaccine&#xD;
           (FavId™) subcutaneously (SC) once on day 1 and sargramostim (GM-CSF) SC once daily on&#xD;
           days 1-4 in months 4-6, 8-11, 14, 16, 18, 20, 22, and 24. Patients with continued&#xD;
           response after completing 2 years of therapy may continue to receive FavId™ and GM-CSF&#xD;
           once every 3 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 56 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2004</start_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival by Kaplan-Meier</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (partial and complete response) at month 6 and any time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression by Kaplan-Meier</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response by cellular or humoral anti-idiotype response positive</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous immunoglobulin idiotype-KLH conjugate vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed indolent B-cell non-Hodgkin's lymphoma of 1 of the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Grade 1 or 2 follicular lymphoma&#xD;
&#xD;
          -  Tumor must be accessible to biopsy or biopsy material available for preparation of&#xD;
             autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId™)&#xD;
&#xD;
          -  Measurable or evaluable disease after node biopsy&#xD;
&#xD;
          -  No mantle cell, marginal zone, MALT-type, small lymphocytic, or grade 3 follicular&#xD;
             (follicular large cell) lymphoma&#xD;
&#xD;
          -  No CNS involvement with lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 2 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other medical or psychiatric disease that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy (active or treated) within the past 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior local radiotherapy allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other prior anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F. Bender, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Favrille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center at Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Sarah Cannon Cancer Center at Centenn</last_name>
      <phone>615-329-7274</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Immunoglobulin Idiotypes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

